SynthesisWorld journal of surgical oncology2022
Clinicopathologic predictors of central lymph node metastases in clinical node-negative papillary thyroid microcarcinoma: a systematic review and meta-analysis.
Synthesis in World journal of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Predicting Risk of Lymph Node Metastasis in Papillary Thyroid Cancer Using miRNAs and Clinicopathological Features.Biochemical genetics · 2026Article
- Nomogram prediction for central lymph node metastasis in papillary thyroid microcarcinoma of the isthmus based on clinical and ultrasound features.Frontiers in surgery · 2026Article
- Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma: a simplified risk scoring system.Frontiers in endocrinology · 2026Article
- Nomogram for postoperative pathological stratification of ≥0.2 cm clinically significant lymph node metastasis burden in pN1 papillary thyroid carcinoma: development and validation using L2 ridge penalized logistic regression.Frontiers in endocrinology · 2026Article
- The relationship between the extent of extrathyroidal extension and lymph node metastasis based on propensity score matching analysis.Gland surgery · 2025Article
- Prospective Validation of ATA Risk Score for Papillary Thyroid Microcarcinoma: An ITCO Real-World Study.The Journal of clinical endocrinology and metabolism · 2025Observational
- Predictive Factors of Lymph Node Metastasis in Papillary Thyroid Microcarcinoma (PTMC).Medicina (Kaunas, Lithuania) · 2025Article
- Development and validation of a multidimensional machine learning-based nomogram for predicting central lymph node metastasis in papillary thyroid microcarcinoma.Gland surgery · 2025Article
- Clinical and morphological predictors of metastasis in papillary thyroid microcarcinoma.Frontiers in endocrinology · 2025Article
- The role of intraoperative central lymph node biopsy in the treatment of clinically low-risk PTMC.Endocrine · 2024Article
- Prognostic factors for aggressiveness in subcentimeter papillary thyroid carcinoma: impact of tumor size and lymph node metastases.Archives of endocrinology and metabolism · 2024Article
- Construction and validation of a diagnostic model for high-risk papillary thyroid microcarcinoma.Frontiers in endocrinology · 2024Article
- Application of ultrasound elastography and radiomic for predicting central cervical lymph node metastasis in papillary thyroid microcarcinoma.Frontiers in oncology · 2024Article
- Article
- A prediction model for identifying high-risk lymph node metastasis in clinical low-risk papillary thyroid microcarcinoma.BMC endocrine disorders · 2023Article
- Initial ablation ratio predicts the recurrence of low-risk papillary thyroid microcarcinomas treated with microwave ablation: a 5-year, single-institution cohort study.Endocrine connections · 2023Article
- A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma.BMC cancer · 2023Article
- Prophylactic Central Neck Lymph Node Dissection Adds No Short-Term Benefit to Total Thyroidectomy for Differentiated Thyroid Cancer.Medicina (Kaunas, Lithuania) · 2023Article
- Exploring risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: construction of a novel population-based predictive model.BMC endocrine disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe presence of central lymph node metastases (CLNM) has been suggested as a risk factor for poorer prognosis and recurrence in papillary thyroid microcarcinoma (PTMC). However, the clinicopathologic factors for CLNM in clinical node-negative (CN0) PTMC were not well defined. This study aimed to perform a systematic review and meta-analysis to investigate the significant clinicopathologic predictors of CLNM in CN0 PTMC.
methodsA systematic literature search was performed in PubMed, Embase, Cochrane Library, and Web of Science. Case-control studies on the association of clinicopathologic risk factors with CLNM in CN0 PTMC were included.
resultsThirteen eligible studies involving 6068 patients with CN0 PTMC were included. From the pooled analyses, male (odds ratio [OR]: 2.07, 95% CI: 1.49-2.87, P < 0.001), multifocality (OR: 1.88, 95% CI: 1.54-2.29, P < 0.001), tumor size > 5 mm (OR: 1.84, 95% CI: 1.55-2.18, P < 0.001), and extrathyroidal extension (OR: 1.96, 95% CI: 1.30-2.95, P = 0.001) are significantly associated with increased risk of CLNM in CN0 PTMC. A sample size with a cutoff point of 200 was identified as the source of heterogeneity for sex according to meta-regression (t = 3.18, P = 0.033). Then, the subgroup analysis of male was performed, which illustrated that male increased the risk of CLNM in the small sample group (SG) and the large sample group (LG) by 6.11-folds and 2.01-folds, respectively (SG: OR, 6.11, 95% CI, 3.16-11.81, P < 0.001; LG: OR, 2.01, 95% CI, 1.65-2.46, P < 0.001).
conclusionsMale, multifocality, tumor size > 5 mm, and extrathyroidal extension may be reliable clinical predictors of CLNM in CN0 PTMC. Moreover, prophylactic central lymph node dissection should be considered in surgical decision-making for CN0 PTMC patients, who are male, multifocal, with tumor size > 5 mm, and with extrathyroidal extension.
trial registrationCRD42021242211 (PROSPERO).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.